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Atherosclerosis is an inflammatory disorder that can evolve into an acute clinical event by plaque development, rupture, and thrombosis. Plaque
vulnerability represents the susceptibilityof a plaque to rupture and to result in an acute cardiovascular event. Nevertheless, plaquevulnerability is
not an established medical diagnosis, but rather an evolving concept that has gained attention to improve risk prediction. The availability of high-
resolution imaging modalities has significantly facilitated the possibility of performing in vivo regression studies and documenting serial changes in
plaque stability. This review summarizes the currently available non-invasive methods to identify vulnerable plaques and to evaluate the effects of
the current cardiovascular treatments on plaque evolution.
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Introduction
Atherosclerosis is a systemic, lipid-driven inflammatory disease of the
arterial wall leading to multifocal plaque development. Despite great
advances in cardiovascular medicine, atherosclerosis remains the
foremost cause of death in developed industrialized countries and
has become the leading cause of death globally.
While most plaques remain asymptomatic, some become ob-
structive and might cause symptoms because of impaired maximal
blood flow. Alternatively, atherosclerosis may assume another pre-
clinical form associatedwith potentially devastating effects: the devel-
opment of often non-obstructive, but ‘unstable’ arterial plaques that
may rupture and provokeacute thrombosis,1,2 causing acutemyocar-
dial infarction, stroke, or sudden death.3
It has been shown that vulnerable plaque is often less stenotic and,
hence, is not detected as clinically significant stenosis with conven-
tional methods.1,2,4 On the other hand, plaques with high-grade sten-
osis are not necessarily associated with major events such as stroke
or myocardial infarction.1,2,4 Before major events happen, smaller
plaque erosions with subsequent small thrombus layers may lead
to less severe clinical findings, such as unstable angina without infarc-
tion or transient ischaemic attacks (TIAs).1,2,4,5 Thus, early detection
of vulnerable plaque is of great clinical value because proper choice of
prevention strategies may reduce the risk of major cardiovascular
events.6
The archetypal presumed rupture-prone (vulnerable) plaque con-
tains a large and soft lipid-rich necrotic core covered by a thin,
inflamed fibrous cap1 infiltrated by macrophages and T cells.7 The
release of cytokines and proteinases from these cells stimulates
breakdown of cap collagen and smooth muscle cell apoptosis and
thereby promotes plaque rupture.7 Thus, plaque inflammation and,
in particular, the degree of macrophage infiltration are important
predictors of plaque rupture and embolic events.8
Recently, the term ‘vulnerable patient’ has been introduced to in-
dicate an individual with a high likelihood of experiencing a cardiac
event, which is likely to havevulnerable blood (prone to thrombosis),
vulnerable myocardium (prone to arrhythmia), and vulnerable
plaque.9 In this regard, Naghavi et al.10 introduced the concept of a
‘vulnerability index’, which is a composite risk score that comprises
the total burden of atherosclerosis and that indicates the likelihood
that a patient with certain factors would have a clinical event in the
coming year.
Plaque instability has been considered a multivessel phenomenon
and, thus, vulnerable plaques may occur simultaneously in different
parts of the arterial tree in the same individual. Indeed, it has been
shown that patients with an acute coronary syndrome had
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concomitantly multiple unstable plaques in the coronary tree and in
the carotid district.11 Moreover, we recently demonstrated, in
patients with lower extremities peripheral arterial disease (PAD),
the association of unstable femoral plaques with increased risk of
coronary and cerebrovascular events.12,13
Several large clinical trials have demonstrated that one of the most
important strategies to reduce cardiovascular events is the
lipid-lowering therapy with statins,14– 17 and this beneficial effect
has been attributed partly to the ‘stabilization’ of vulnerable ather-
oma.18 On the contrary, little is known about the potential benefits
of other important cardiovascular therapies such as beta-blockers or
renin angiotensin system (RAS) inhibitors on plaque remodelling.19,20
The aim of this review is to critically analyse the currently available
non-invasive methods to identify vulnerable plaques and to evaluate
the effects of the current cardiovascular treatments on plaque evolu-
tion. Characterization of the possible diagnostic procedures neces-
sary to identify the ‘vulnerable’ patient and to optimize his
therapeutic management may become clinically very important to
improve cardiovascular prognosis.
Ultrasonography
High-resolution B-mode ultrasound is a simple, low cost, and reliable
non-invasive method for the evaluation of vascular stenosis and
plaque echogenicity, which is known to be related to the histological
characteristics of the atherosclerotic lesion.21 Examination of carotid
arteries for intima-media thickness (IMT) is a widely used and reliable
marker to reveal the severity of atherosclerosis and to predict the
presence of coronary artery disease (CAD).22– 25 Furthermore, as-
sessment of carotid IMT has also been extensively shown to be a
strong indicator for adversecardiovascular events,24,26 and its regres-
sion with statin therapy may provide enhanced reduction in clinical
coronary event rates.27 –29 In addition, Reilly et al.30 first suspected
that echo patterns in the B-mode image of a carotid plaque could
be related to the composition of the plaque. Investigations of the re-
lationship between cerebral symptoms and morphological charac-
teristics of plaque defined by ultrasound found an association
between clinical cerebral ischaemic events and ulceration, echolu-
cency, intraplaque haemorrhage (IPH), and high lipid content.30 In
particular, ulceration is believed to be important because it deter-
mines exposure of the thrombogenic layers of the plaque, with the
possibility of subsequent thrombus formation.
Over the last decades, echogenicity has been differently defined
and classified according to a variety of criteria. Since 1985, Johnson
et al.31 distinguished plaques in calcified, dense, and soft. Subsequently,
in 1988, Gray-Weale et al.32 described four plaque types, ranging
from dominantly echolucent, to dominantly echogenic with small
areas of echolucency, through two additional types of mixed echo-
genicity. Reillyet al.30 introduced characterization ofplaque structure
into homogeneous, having uniform high- or medium-level echoes,
and heterogeneous, having high-, medium-, and low-level echoes,
and containing areas with echogenicity similar to blood. Other
groups used the criteria of the European Carotid Plaque Study
Group33 since 1994: echo-rich, intermediate, and echolucent, com-
bined with surface and structural characteristics.33,34 The echolucent
plaques were associated with a high content of lipid and intraplaque
haemorrhage, whereas echo-rich plaques contained more calcium
and fibrous tissue.34 Ultrasound could not reliably distinguish
between lipid and IPH, and this is why some studies have combined
these two constituents in the term ‘soft tissue’.33 To summarize,
plaques that appear hypoechoic on B-mode ultrasound (Figure 1)
have a pronounced inflammatory infiltration, a high lipid content,
and are more prone to rupture,35 whereas hyperechoic plaques
consist mainly of fibrous tissue, collagen, and calcium, which make
them more stable.21
To characterize B-mode images of plaques more objectively,
digital image processing or videodensitometric analysis has been
introduced. Using digital image processing, el-Barghouty et al.36
found that the content of soft tissue in the plaque was associated
with a low gray-scale median (GSM) value of the plaque. Conversely,
a high fibrous tissue content was associated with a high GSM value.37
This ultrasonographic index of echogenicity has emerged as an as-
sessment methodology of carotid plaque vulnerability,38 and may
help in the vascular risk stratification in order to target individuals
at increased vascular risk for intensive preventive therapies and to
monitor the effects of anti-atherosclerotic therapies. Interestingly,
many studies have considered whether the lipid-lowering therapy
with statins modifies the echogenicity of atherosclerotic plaques.
Della-Morte et al.39 showed that carotid plaque echogenicity mea-
sured by ultrasonographic gray-scale densitometry decreased after
short-term treatment with atorvastatin. In addition, an intensive
Figure 1: Example of hypo-anechoic carotid plaque (arrow) at
B-mode (A) and duplex (B) ultrasonography. Such low echogenicity
at B-mode ultrasound (plaque type 1, GSM 6.2) is suggestive of high
lipid content, intraplaque haemorrhage, and pronounced inflamma-
tory infiltration. Duplex ultrasound allows to better outline the
plaque.
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long-term atorvastatin therapy increased a GSM score, without re-
gression of plaque size, in patients with carotid stenosis.40 An increas-
ing echogenicity of vulnerable plaque in carotid districts, assessed by
integrated back scatter, is present also in hypercholesterolemic41 and
non-hypercholesterolemic patients with CAD after a short-term
statin therapy.42
A potential beneficial effect of b-blockers on plaque stability,
assessed by GSM in carotid plaques, has been demonstrated
by Ostling et al.19 After 36 months of treatment, plaques were
more echogenic in participants treated with metoprolol CR/XL
and fluvastatin (40 mg once daily) than in those treated with fluvasta-
tin only.
Although this review focuses on the non-invasive imaging of the
vulnerable plaque, it is worth mentioning that atherosclerotic
plaques unapproachable bynon-invasive ultrasonography, such as cor-
onary plaques, can efficiently be assessed by alternative methods, such
as invasive intravascular ultrasound (IVUS) or optical coherence tom-
ography (OCT). IVUS uses an ultrasound transducer on the tip of a
catheter to produce images for the evaluation of plaque size, distribu-
tion and composition, of vascular remodelling and vessel wall distensi-
bility.43 IVUS is also used as a potential application for the identification
of atheromas at risk of rupture.44 In contrast, OCT is an optical ana-
logue of ultrasound imaging, recently proposed as a high-resolution
imaging method for plaque characterization.45 In this regard, it has
been shown that OCT reflects the macrophage content of the
fibrous cap.46 All fibrous plaques, calcifications, and echolucent
regions identified by IVUS are seen in OCT images. Moreover, com-
pared with IVUS, OCT images provide additional morphological infor-
mation, which could be used to improve plaque characterization.47
Contrast-enhanced
ultrasonography
Contrast ultrasound relies on the selective retention of the contrast
agent at specific sites of disease. Different types of targeted contrast
agents have been reported, most of which share in common the pres-
ence of a gas encapsulated by a shell of varying chemical formula-
tion.48 Targeted micro-bubbles have undergone experimental
evaluation to visualize cell surface structures or other features
implicated in plaque rupture, such as neovascularization. A simple
approach for targeting has been to take advantage of the natural
ability of certain microbubble shell constituents to bind directly or
indirectly to cells that have undergone pathological activation.49
A more specific approach has been to attach disease-targeted
ligands, such as antibodies, small peptides, and glycoproteins, to the
surface of ultrasound contrast agents. Accordingly, endothelial cell
adhesion molecules, such as intracellular adhesion molecule-1, vas-
cular cell adhesion molecule-1 (VCAM-1),50 and P-selectin,51 that
play a critical role in the progression of atherosclerosis, are a
popular target for micro-bubbles. Imaging of VCAM-1 and P-selectin
has been used to detect the earliest stages of atherosclerotic disease
even before the development of fatty streaks, supporting the notion
that molecular imaging could be used to guide the use of the next
generation of preventive therapies.
Unfortunately, a limitation of molecular ultrasound imaging is
that, first, only intravascular events can be accessed; then, a critical
threshold amount of molecular expression may be needed to see at-
tachment.52 Nevertheless, contrast ultrasound provides a good
balance between spatial resolution and sensitivity to detect contrast
agent, and these features make this technique well positioned among
non-invasive methods in the assessment of the vulnerable plaque.
Immunoscintigraphy
Immunoscintigraphy is a non-invasive alternative technique based on
the administration of radioactive tracers that localize into vulnerable
plaque and the subsequent scan for radioactive emissions. Many
radionuclide-labelled molecules have been proposed to investigate
atherosclerotic plaques, such as low-density lipoproteins,53 haema-
toporphyrin derivatives,54 fibronectin,55 immunoglobulins,56 and
platelets.57,58 Other investigations focused on antifibrin antibodies59
directed against D-dimers of cross-linked fibrin. The presence of in-
soluble fibrin represents an accurate marker of the activation of the
coagulation cascade in the vessel lumen, potentially offering also the
opportunity of an enhanced imaging, due to the lower background
activity even in the absence of thrombi, as it is known that layers of
insoluble fibrin are present inside uncomplicated atherosclerotic
plaques.60
Positron emission tomography
Positron emission tomography (PET) with F-18-fluorodeoxyglucose
(FDG) is a molecular imaging technique that is highly sensitive to
metabolically active processes using glucose as a fuel. FDG is a
glucose analogue that is taken up by cells in proportion to their meta-
bolic activity. Recently, arterial FDG-PET imaging has been extended
to the study of the pathogenic mechanisms of atherosclerosis.61 FDG
could be considered a marker of inflammation since macrophages,
key inflammatory cells in plaque, have higher glucose metabolism
than both surrounding plaque cells and healthy artery walls.
Tawakol et al.62 showed that, in a rabbit model of atherosclerosis,
there is a strong correlation between macrophage density and
FDG uptake, and reported similar findings in patients with carotid
artery disease, supporting the hypothesis that a higher FDG uptake
identifies a more vulnerable plaque. Some studies have shown visual-
ization of FDG uptake in coronary artery plaques.63–65 However,
several technical issues limit its application: FDG uptake in adjacent
structures such as the myocardium, cardiac motion during PET acqui-
sition, and partial volume effect due to small coronary artery and the
size of plaques. Furthermore, arterial FDG uptake positively corre-
lates with levels of several circulating inflammatory biomarkers and
molecular gene up-regulation of enzymes known to degrade the
cellular matrix of vulnerable plaque,61,62 such as the matrix metallo-
proteinase (MMP) family, whose activity has been associated with
advanced atherosclerosis and plaque rupture.66
In the first prospective study using FDG-PET to quantify inflamma-
tion in atherosclerosis, Rudd et al.61 measured increased carotid
artery FDG uptake in symptomatic lesions of patients with recent
TIA. Furthermore, it has been shown that inflammatory activity of
plaques can be assessed by FDG-PET not only in carotid and other
brain supplying arteries, but also in the aorta, iliac, femoral,67 and cor-
onary arteries.65 The different distributions of FDG uptake may
reflect the different stages of atherosclerosis progression: a higher
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FDG uptake reveals concurrent extensive and advanced atheroscler-
osis.68 In fact, there is a significant correlation between FDG uptake
and cardiovascular risk factors such as hypertension, smoking, hyper-
lipidaemia, being overweight, Type II diabetes, and a family history of
CAD.69 Thus, higher FDG uptake might contribute to the identifica-
tion of a subgroup of patients at high risk for cardiovascular events.63
A recent study has shown that FDG uptake in atherosclerotic
plaques is predictive of the future occurrence of cardiovascular
events in neoplastic patients.70 Indeed, FDG-PET could be used
not only to predict the risk of future plaque rupture and to identify
a subset of high-risk patients who need of intensified medical
therapy or carotid surgery to prevent stroke, but also to monitor
the effectiveness of the reduction of vascular inflammation in re-
sponse to lifestyle intervention on cardiovascular risk factors71 or
to pharmacological treatments. Indeed, it has been demonstrated
both in a rabbit model72 and in human patients73 that statin therapy
is able to reduce FDG uptake. In conclusion, the identification of
FDG uptake in vascular plaques may have important clinical implica-
tions to predict and prevent future cardiovascular events.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a safe and non-invasive tech-
nique that, operating without X-rays, can be used to evaluate athero-
sclerosis or to guide therapy, since it possesses the superb spatial
resolution necessary to image small-scale pathological findings such
as atherosclerotic disease progression. However, it is a relatively
signal-insensitive technique when compared with computed tomog-
raphy (CT) or PET, requiring long scanning times to improve spatial
resolution and to overcome its low temporal resolution.
As far as atherosclerotic lesions regard, MRI is able to characterize
soft tissue components of plaque. It can identify, with high accuracy,
sensitivity, and specificity, the lipid core74 and thin and/or ruptured,
unstable, caps,75 which are strongly associated with having had a
recent TIA or stroke.76 Moreover, MRI has emerged as a reliable
andhighly accurate tool todetect IPH in vivo,77 whichhighly correlates
with plaque instability.
Target-specific contrast agents have recently been developed in
order to better discriminate plaque components and then to
overcome some MRI limitations, such as long time data acquisition.
So far, molecular agents targeted to adhesion molecules,78 or high-
density lipoprotein,79 MMPs,80 and macrophage scavenger recep-
tors81 have been tested at the preclinical level, and agents targeted
to fibrin82 and macrophages83 have already been used in patients.
One of the earliest applications of nanotechnology in MRI involved
the use of paramagnetic iron oxide particles. Ruehm et al.84 demon-
strated spontaneous phagocytic uptake of superparamagnetic iron
oxide and ultra superparamagnetic iron oxide particles by macro-
phages in atherosclerotic plaque in hyperlipidaemic rabbits. In 2003,
this finding was extended to human plaque83 (Figure 2). Recently,
with the advent of fibrin-binding molecular MRI contrast agents and
advances in coronary MRI techniques, it has become possible to
obtain a direct imaging of coronary thrombosis.82,85
Furthermore, MRI has been used to assess the efficacy of anti-
angiogenic strategies on the stabilization of aortic atherosclerotic
plaques. Since IPH is considered a potential contributor to plaque de-
stabilization, drugs acting specifically on neoangiogenic growth might
reduce plaque vulnerability. Winter et al.86 demonstrated the acute
anti-angiogenic effects of fumagillin, an antagonist of anb3 integrin,
which is an adhesion molecule that promotes the formation of new
blood vessels. In this study, the effect of anb3-targeted fumagillin
nanoparticles was prolonged when combined with the use of
atorvastatin, thus representing a potential anti-angiogenic and
plaque stabilization strategy. Moreover, Moulton et al.87 showed that
the inhibition of neovascularization by angiostatin reduced macro-
phage accumulation and plaque progression in mice. Subsequently,
Figure 2: Example of plaque detection by contrast-enhanced MR angiography. Coronal gadolinium-enhanced MR angiography shows aneuris-
matic dilatation of the abdominal aorta and iliac bifurcation (arrows) (A). Axial MR images show severe descending aortic plaque (B and C); note
the relatively lucent lipid core (arrows).
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Cortiet al.88 haveprospectively shownthat in patientswith carotidor
aortic plaques treated with statins for at least 1 year, the earliest ap-
preciable change was a regression in plaque size. Longer follow-up
indicated that regression of atherosclerotic lesions continues for at
least 24 months, and that progressive remodelling of the arterial
wall produces a significant increase in luminal area.89 These data
have also been confirmed by Zhao et al.,90 demonstrating how inten-
sive lipid-lowering therapy significantly depletes carotid plaque lipid
after 1 year of treatment, and continues in the second year. Subse-
quently, West et al.91 have studied the effects of lowering lipid strat-
egies, with simvastatin 40 mg alone or simvastatin 40 mg plus
ezetimibe 10 mg, on the regression of atherosclerotic lesions mea-
sured by MRI in the superficial femoral artery in patients affected
by PAD. This study demonstrated that statin initiation with or
without ezetimibe in statin-naı¨ve patients halts progression of periph-
eral atherosclerosis whereas, when ezetimibe is added to patients
previously on statins, peripheral atherosclerosis progressed.91
Computed tomography
Recent technological advances led to a growing interest in CT as a
tool for the non-invasive characterization of atherosclerotic
disease. When compared with MRI, CT is more signal-efficient and
is able to provide high-spatial resolution images of the entire coron-
ary arterial tree in a short period of sustained respiration, thereby re-
ducing scanning time. By virtue of its ability to measure local tissue
attenuation, multidetector (MD) CT also allows imaging of the
vessel wall, potentially providing insights into the characteristics
and extent of intramural atherosclerosis.92 MDCT can also help
detecting some of the features associated with plaque vulnerability,
such as more positive remodelling, the presence of spotty calcifica-
tions, and a lower plaque density (,30 Hounsfield units).93 Figure 3
shows an example of contrast-enhanced CT angiography detection
of plaques of different grade.
In the context ofmolecular imaging of intraplaque inflammation, CT
has shown promising preliminary results in animal models, using
targeted nanoparticle contrast agents, but the feasibility and clinical
applicability of CT for molecular imaging of plaque vulnerability still
awaits clinical translation to humans.94
Monitoring atheroma progression using serial CT has been used to
characterize the natural history of atherosclerosis and the effect of
anti-atherosclerotic therapies. Uehara et al.95 quantitated the effect
of 10 mg atorvastatin on the size and content of non-calcified coron-
ary plaques (NCPs) using MDCT and by comparison of LDL choles-
terol levels. In this study, atorvastatin decreased NCP area if LDL
cholesterol levels were sufficiently reduced, in agreement with the
result of studies using IVUS.
Soeda et al.96 demonstrated that rosuvastatin therapy (2.5–10 mg
for24weeks)wasable to reduce the volume of lipid cores in lipid-rich
coronary plaques, and increased their CT attenuation value, report-
ing that dual-source CT is an effective modality for the non-invasive
evaluation of high-risk coronary plaques in patients with acute
Figure 3: Example of plaque detection by contrast-enhanced CT angiography. Some calcified plaques can be seen in the axial views of the supra-
renal (upper left panel) and sub-renal (lower left panel) abdominal aorta. Multiple calcified plaques can be seen on multiplanar reformatting coronal
CT (right panel) in the abdominal aorta and iliac arteries.
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coronary syndromes. Furthermore, using MDCT, Suzuki et al.20
demonstrated that the combination therapy of an RAS inhibitor
with statin is more effective than statin alone in inhibiting athero-




Several imagingplatforms are currentlyavailable for targeted vascular
imaging to acquire information on both anatomy and pathophysi-
ology in the same imaging session using hybrid technology, such as
PET/CT or PET/MRI. Indeed, PET imaging has relatively low spatial
resolution, mandating the use of concurrent structural imaging
(CT or MRI) to guide localization of the FDG signal, revealing
whether the plaque is actually metabolically active or not.
Hybrid PET/CT enables measurement of functional and structural
features of atherosclerosis, in which FDG uptake detects plaques
with an ongoing inflammatory process, whereas CT identifies
chronic calcification as a manifestation of the late stage of the
disease. Examplesofplaquedetectionby hybrid PET/CTaredepicted
in Figures 4 and 5.
FDG-PET/CT has also been used to detect the anti-inflammatory
effect of short-term statin treatment on aortic lesions, in correlation
with the circulating inflammatory biomarkers.97 In particular, a
significant reduction of FDG activity was reached after atorvastatin
treatment. These findings provide in vivo evidence that the medium
dose of atorvastatin (40 mg) might have a beneficial effect on
plaque stability in 12 weeks, suggesting that a relatively low dose
and a short treatment interval are sufficient to observe changes in
plaque burden.97 Ishii et al.98 prospectively assessed the effect of
6-month therapy with 5 vs. 20 mg of atorvastatin on reducing FDG
uptake in aortic plaques with PET/CT, and showed that only
Figure 4: Example of plaque detection by hybrid PET/CT.
Contrast-enhanced middle-chest axial CT view shows parietal
thin abnormality (thrombosis) of the ascending and descending
aorta (A). Hybrid PET/CT scan demonstrates areas of inhomogen-
eous parietal FDG uptake in the thoracic aorta (arrows), suggesting
an ongoing inflammatory process (B).
Figure 5: Example of plaque detection by hybrid PET/CT. Contrast-enhanced head, neck, and chest coronal multiplanar reformatting CT scan
shows parietal thin abnormality of both carotid arteries and the aortic arch (A); PET (B) and hybrid PET/CT (C) scans show areas of increased
FDG uptake in carotid arteries and aortic arch (arrows).
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atorvastatin 20 mg significantly reduced plaque inflammation. An
example of evaluation by hybrid PET/CT of regression of plaque
inflammation is depicted in Figure 6.
Emerging hybrid PET/MRI has considerable potential for cardio-
vascular imaging.99 In a recent study,100 the relationship between in-
flammation in PET and morphological features of carotid plaques
associated with high risk of clinical events, such as lipid deposition, re-
modelling, and luminal irregularities, was studied in patients with PET
and MRI co-registration. Carotid inflammation increased with the
number of high-risk morphological features observed, supporting
the concept that plaque inflammation and composition are closely
linked. In the future, with new hardware developments and the intro-
duction of combined PET and MRI scanners, it would be possible to
add the most attractive aspects of both modalities in order to have a
more profound look into the biology of atherosclerotic plaques.
Conclusions and clinical
implications
Atherosclerosis involves undetected vascular changes, like calcifica-
tions or inflammatory infiltration of the vessels. The identification
of preclinical atherosclerotic lesions allows the application of appro-
priate strategies to prevent its progression and promote its regression.
Epidemiological studies have shown that major adverse cardiovascular
events result from vulnerable plaque rupture,1,2,4,10,101,102 confirming
that biological composition and inflammatory state of an atheroscler-
otic plaque, rather than its degree of stenosis or size, may be the major
determinants for acute clinical events. Thus, the opportunity to non-
invasively and prospectively monitor vulnerable plaques, before their
disruption and clinical expression, is a laudable and useful goal.
All the approaches discussed above are promising tools for the
non-invasive imaging of the known manifestations of atherosclerotic
plaque; however, their widespread clinical applicationwill require the
availability of non-toxic probes, imaging platforms, and demonstra-
tion of cost-effectiveness. The ideal imaging modality should be
able to address the stabilization of vulnerable plaques with the
most recent therapeutic strategies. Such a technique needs to be
non-invasive, reliable, inexpensive, and not harmful since serial
exams have to be performed over time.
The above-mentioned non-invasive strategies may help to assess
the effectiveness of therapy and to frame a subset of high-risk patients
exposed to a more severe cardiovascular prognosis. However, there
is currently no evidence supporting different therapeutic strategies in
patients with and without vulnerable plaques. Therefore, the pres-
ence of calcified plaques cannot justify a milder treatment. Actually,
optimal management of unstable plaques remains to be defined
and tested prospectively, since it is unclear if invasive ‘cool down’
of inflamed atherosclerotic lesions has a favourable risk–benefit
ratio. The identification of vulnerable plaques may, probably,
suggest to the physician to have a ‘special attention’ towards these
potentially higher cardiovascular risk patients. Thus, the appropriate
use of any plaque imaging modality and consecutive interventions
needs to be investigated in prospective clinical trials, ultimately
leading to guidelines for identification, risk stratification, and
therapy of patients with unstable plaques.
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